Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for ...

Sales rise 6.67% to Rs 1.92 crore. Net Loss of Vertex Securities reported to Rs 0.41 crore in the quarter ended December 2025 as against net loss of Rs 0.44 crore during the previ ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...

Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

Vertex, Inc. (NASDAQ:VERX) Q4 2025 Earnings Call Transcript February 11, 2026 Vertex, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $0.17. Operator: Good day, and ...

Sales decline 2.61% to Rs 70.79 crore. Net profit of Subex reported to Rs 2.93 crore in the quarter ended December 2025 as against net loss of Rs 3.25 crore during the previous qu ...

VERTEX SECURITIES LTD - Board Meeting Outcome for Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations, 2015 - ...

"This matter involves unregistered municipal advisory activity by Ford Research and its president, founder, owner, and sole ...